Product Name :
AT-56
Description:
AT-56 is an orally active and selective inhibitor of lipocalin-type prostaglandin (PG) D synthase (L-PGDS) with Ki of 75 μM and IC50 of 95 μM.
CAS:
162640-98-4
Molecular Weight:
397.52
Formula:
C25H27N5
Chemical Name:
4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine
Smiles :
C1CN(CCCCC2=NNN=N2)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21
InChiKey:
LQNGMDUIRLSESZ-UHFFFAOYSA-N
InChi :
InChI=1S/C25H27N5/c1-3-9-22-19(7-1)12-13-20-8-2-4-10-23(20)25(22)21-14-17-30(18-15-21)16-6-5-11-24-26-28-29-27-24/h1-4,7-10,12-13H,5-6,11,14-18H2,(H,26,27,28,29)
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
AT-56 is an orally active and selective inhibitor of lipocalin-type prostaglandin (PG) D synthase (L-PGDS) with Ki of 75 μM and IC50 of 95 μM.|Product information|CAS Number: 162640-98-4|Molecular Weight: 397.52|Formula: C25H27N5|Chemical Name: 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-[4-(2H-tetrazol-5-yl)butyl]-piperidine|Smiles: C1CN(CCCCC2=NNN=N2)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21|InChiKey: LQNGMDUIRLSESZ-UHFFFAOYSA-N|InChi: InChI=1S/C25H27N5/c1-3-9-22-19(7-1)12-13-20-8-2-4-10-23(20)25(22)21-14-17-30(18-15-21)16-6-5-11-24-26-28-29-27-24/h1-4,7-10,12-13H,5-6,11,14-18H2,(H,26,27,28,29)|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO 80 mg/mL (201.{{Nitroxoline} MedChemExpress|{Nitroxoline} Anti-infection|{Nitroxoline} Biological Activity|{Nitroxoline} References|{Nitroxoline} manufacturer|{Nitroxoline} Epigenetic Reader Domain} 25 mM)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Etanercept} medchemexpress|{Etanercept} Apoptosis|{Etanercept} Protocol|{Etanercept} Description|{Etanercept} manufacturer|{Etanercept} Cancer} |Shelf Life: ≥12 months if stored properly.PMID:24428212 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|AT-56 inhibits human and mouse L-PGDSs in a concentration (3–250 μm)-dependent manner. AT-56 inhibits the L-PGDS activity in a competitive manner against the substrate PGH2 (Km = 14 μm) with a Ki value of 75 μm. AT-56 inhibits the production of PGD2 by L-PGDS-expressing human TE-671 cells after stimulation with Ca2+ ionophore (5 μm A23187) with an IC50 value of about 3 μm without affecting their production of PGE2 and PGF2α.|In Vivo:|Orally administered AT-56 (References:|Daisuke Irikura, et al. J Biol Chem. 2009 Mar 20;284(12):7623-3Products are for research use only. Not for human use.|